RecruitingNot ApplicableNCT06451536

Ga-68 FAPI PET Before Immunotherapy

Prognostic Significance of Ga-68 FAPI PET Before Immunotherapy in Pleural Mesothelioma


Sponsor

Ankara University

Enrollment

30 participants

Start Date

Apr 30, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

It is aimed to evaluate FAP expression and its success in predicting treatment response before immunotherapy used in the treatment of malignant mesothelioma with Ga68 FAPI PET/CT imaging, which allows in vivo evaluation of FAP expression, which is thought to be associated with immunosuppression and resistance to immunotherapy.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study uses a special type of PET scan (called FAPI PET) to image patients with pleural mesothelioma — a cancer of the lining around the lungs — before they start immunotherapy. The goal is to see whether this scan can predict who will respond better to immunotherapy. **You may be eligible if...** - You have been diagnosed with pleural mesothelioma confirmed by biopsy - You are scheduled to receive immunotherapy (anti-PD-L1 and/or anti-CTLA-4 antibodies) as your first or second treatment - You are in reasonably good health (not severely limited by your illness) **You may NOT be eligible if...** - Your illness severely limits your daily activities (ECOG score above 2) - You are unwilling to provide informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTGa-68 FAPI PET/CT

imaging of FAP expression of tumor before immunotherapy


Locations(1)

Ankara University School of Medicine

Ankara, Turkey (Türkiye)

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06451536


Related Trials